Cadrenal Therapeutics, Inc. CVKD
1.15
(0.05)
(4.17%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow CVKD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
3.02 | 2.72 | 2.68 | 3.73 |
Net Debt/EBITDA |
1.41 | 1.31 | 0.92 | 0.72 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.85 | 1.20 | 0.67 | |
Capex/Depreciation |
(4.50) | 0.00 | 0.00 | 2.80 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.15) | (1.29) | (1.25) | (0.77) | |
Cash per Share |
1.89 | 2.01 | 0.96 | 0.82 | |
Shareholders Equity per Share |
1.34 | 1.37 | 0.75 | 1.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.34 | 1.37 | 0.75 | 1.40 | |
Free Cash Flow |
(2.36) | (2.57) | (3.00) | (2.23) | |
Working Capital |
2.73 | 2.73 | 1.79 | 4.09 | |
Capital Expenditures |
0.00 | 0.00 | — | 0.00 | |
Net Current Asset Value |
2.73 | 2.73 | 1.79 | 4.09 | |
| Other line items | |||||
Quick Ratio |
2.86 | 2.53 | 2.17 | 3.39 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.15) | (1.29) | (1.25) | (0.77) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.03 | 0.02 | 0.02 | 1.35 | |
Average Payables |
0.56 | 1.08 | 1.05 | 0.88 | |
Average Assets |
4.38 | 7.23 | 5.41 | 5.78 | |
Average Common Equity |
3.07 | 5.09 | 3.96 | 4.20 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates